Gilead Sciences, Inc. — Company profile
Healthcare · Drug Manufacturers - General · United States
Last price 165.61 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 205.35B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Details
| Name | Gilead Sciences, Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 17000 |
| Founded | 1987 |
| Ipo Date | 1992-01-22 |
| Ceo | Daniel Patrick O'Day |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US3755581036 |
| Cusip | 375558103 |
| Cik | 0000882095 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Daniel Patrick O'Day | Chairman and Chief Executive Officer |
| Andrew D. Dickinson | Executive Vice President and Chief Financial Officer |
| Johanna Mercier | Chief Commercial and Corporate Affairs Officer |
| Dr. Dietmar P. Berger M.D., Ph.D. | Chief Medical Officer |
| Erin E. Burkhart | Senior Vice President, Controller and Chief Accounting Officer |
| Jacquie Ross C.F.A. | Senior Vice President of Treasury and Investor Relations |
| Keeley M. Cain Wettan | Executive Vice President, General Counsel of Legal and Compliance and Secretary |
| Jyoti K. Mehra | Executive Vice President of Human Resources |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation and Portfolio |
| Dr. Flavius Martin M.D. | Executive Vice President of Research |
Contact
| Address | 333 Lakeside Drive, Foster City, California 94404, United States |
| Phone | 650 574 3000 |
| Website | https://www.gilead.com |